JP2022536653A5 - - Google Patents

Info

Publication number
JP2022536653A5
JP2022536653A5 JP2021573215A JP2021573215A JP2022536653A5 JP 2022536653 A5 JP2022536653 A5 JP 2022536653A5 JP 2021573215 A JP2021573215 A JP 2021573215A JP 2021573215 A JP2021573215 A JP 2021573215A JP 2022536653 A5 JP2022536653 A5 JP 2022536653A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
akg
composition according
sasp
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536653A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036974 external-priority patent/WO2020252005A1/en
Publication of JP2022536653A publication Critical patent/JP2022536653A/ja
Publication of JP2022536653A5 publication Critical patent/JP2022536653A5/ja
Pending legal-status Critical Current

Links

JP2021573215A 2019-06-10 2020-06-10 老化関連分泌表現型を修整する方法および組成物 Pending JP2022536653A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962859623P 2019-06-10 2019-06-10
US62/859,623 2019-06-10
PCT/US2020/036974 WO2020252005A1 (en) 2019-06-10 2020-06-10 Methods and compositions for altering senescence associated secretory phenotype

Publications (2)

Publication Number Publication Date
JP2022536653A JP2022536653A (ja) 2022-08-18
JP2022536653A5 true JP2022536653A5 (https=) 2023-06-16

Family

ID=73781254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573215A Pending JP2022536653A (ja) 2019-06-10 2020-06-10 老化関連分泌表現型を修整する方法および組成物

Country Status (7)

Country Link
US (1) US20220241229A1 (https=)
EP (1) EP3980000A4 (https=)
JP (1) JP2022536653A (https=)
CN (1) CN114126599A (https=)
AU (1) AU2020293094A1 (https=)
CA (1) CA3142781A1 (https=)
WO (1) WO2020252005A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102833111B1 (ko) 2018-09-25 2025-07-10 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니 칼슘 알파-케토글루타레이트의 제조 방법
DE102021111719A1 (de) * 2021-05-05 2022-11-10 Henkel Ag & Co. Kgaa Erhalt der Haarstruktur gegenüber Umwelteinflüssen umfassend ein Phenol und multivalente Ionen
US20250376678A1 (en) * 2022-04-01 2025-12-11 Japanese Foundation For Cancer Research Therapeutic agent for cancer, testing assistance method, and screening method for therapeutic agent
EP4561696A1 (en) * 2022-06-30 2025-06-04 Mechanobiologics, Inc. Reversal of cellular senescence by treatment with low frequency ultrasound
CN115813784A (zh) * 2022-11-28 2023-03-21 麦吉丽生物科技有限公司 α-酮戊二酸、含有α-酮戊二酸的米发酵液在制备皮肤炎症抑制剂中的用途
WO2024123738A1 (en) * 2022-12-06 2024-06-13 Ponce De Leon Health Designated Activity Company Compositions and methods for treating diseases responsive to akg-vitamin b coadministration

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198465A (en) * 1991-06-19 1993-03-30 Dioguardi Francesco S Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
CA2447357A1 (en) * 2001-05-22 2002-11-28 Gene Logic, Inc. Molecular toxicology modeling
DK1824470T3 (da) * 2004-12-17 2014-08-18 Cash Alan Brian Fremgangsmåde til forlængelse af levetiden og forsinke starttidspunktet for alders-relateret sygdom
WO2007053943A1 (en) * 2005-11-08 2007-05-18 Multi Formulations Ltd. The use of compositions comprising ketoacids and amino acids for increasing muscle mass and muscle performance
PL379512A1 (pl) * 2006-04-21 2007-10-29 Sgp & Sons Ab Nowe metody i ich zastosowanie
MX2009013937A (es) * 2007-07-02 2010-04-30 Entress Ab Nuevo uso de compuestos quimicos farmacologicamente activos conocidos.
DE102009016119A1 (de) * 2009-04-03 2010-10-14 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren zur Unterstützung der Diabetestherapie
JP2014511890A (ja) * 2011-04-18 2014-05-19 ネステク ソシエテ アノニム α−HICA及びα−ケトグルタル酸を含有する栄養組成物
US20150328176A1 (en) * 2013-01-25 2015-11-19 Winning The Fight Inc. Composition for treatment of neurodegenerative disease
IL286427B2 (en) * 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
KR20160111529A (ko) * 2014-02-12 2016-09-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 노화 및 연령 관련 질환 및 증상의 치료를 위한 조성물 및 방법
CN106963749A (zh) * 2017-03-23 2017-07-21 华南农业大学 α‑酮戊二酸(盐)在抗疲劳和提高肌肉运动力量方面的应用
SG10202107237SA (en) * 2017-04-25 2021-08-30 Buck Inst Res Aging Formulations for extending lifespan and healthspan
CN108774203A (zh) * 2018-06-25 2018-11-09 北京未蓝时代科技有限公司 一种延缓哺乳动物细胞和机体衰老的化合物及其应用
WO2020086733A1 (en) * 2018-10-24 2020-04-30 Ponce De Leon Health Designated Activity Company Nicotinamide riboside compositions for healthspan extension

Similar Documents

Publication Publication Date Title
JP2022536653A5 (https=)
Tsujino et al. Pulmonary activation of vitamin D3 and preventive effect against interstitial pneumonia
JP7152552B2 (ja) 細胞外小胞による疾患の診断方法
van Nieuwenhuijze et al. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis
AU2026202508A1 (en) Matrix bound vesicles (mbvs) containing il-33 and their use
CA3097025A1 (en) Biomarkers for graft-versus-host disease
US10006003B2 (en) Compositions and methods for flowable allograft amniotic tissue
Takahashi et al. Porphyromonas gingivalis Mfa1 fimbria putatively binds to TLR2 and induces both IL-6 and IL-8 production in human bronchial epithelial cells
Wielińska et al. Interleukin 6 gene polymorphism is associated with protein serum level and disease activity in Polish patients with rheumatoid arthritis
Fu et al. CD81+ senescent-like fibroblasts exaggerate inflammation and activate neutrophils via C3/C3aR1 axis in periodontitis
Tirelli et al. Effects of methylglyoxal on intestine and microbiome composition in aged mice
Hirasawa et al. Short-term amiodarone treatment attenuates the production of monocyte cytokines and chemokines by C-reactive protein and improves cardiac function in patients with idiopathic dilated cardiomyopathy and ventricular tachycardia
Martin et al. Whole blood transcriptomics reveals granulocyte colony‐stimulating factor as a mediator of cardiopulmonary bypass‐induced systemic inflammatory response syndrome
Yan et al. Mycoplasma ovipnuemoniae impairs the immune response of sheep and suppresses neutrophil function by inhibiting S100A9
US20180311199A1 (en) Combination treatment for inflammatory diseases
JP2013525820A5 (https=)
CN117285595B (zh) 一种具有肠屏障保护功能的五肽lk5及其应用
JP5528351B2 (ja) スクリーニング方法、該スクリーニング方法で選ばれた物質を含有する組成物、結合物質
TWI770565B (zh) 一種用以篩選藥物的方法,以及該藥物於治療乾癬的用途
Rakhmatullina et al. Immune system of periodontium and identification of professional conditions in limestone quarry workers
CN121987626A (zh) 麦角硫因制剂在制备用于重塑炎症相关dna甲基化谱和/或降低表观遗传年龄的产品中的应用
Van Bruggen et al. Neutrophil Peptidylarginine Deiminase 4 is Essential for Detrimental Age-related Cardiac Remodeling & Dysfunction in Mice
Hathaway et al. Nuclear‐mitochondrial crosstalk in the heart during diabetes mellitus–the impact on RNA in mitochondrial subpopulations
CN105412929B (zh) Il7r‑3’utr在调控维甲酸相关孤儿核受体表达中的应用
Helsen et al. Annemarie EM van Nieuwenhuijze1, 2, 3, Fons A. van de Loo1, Birgitte Walgreen1, Miranda Bennink1